Genetic activation of hepatic steatosis caused substantial increases in ALT and AST levels, possibly because the contribution of risperidone to fatty liver disease development was mediated by increased mRNA expression of molecular mechanisms of lipid accumulation in the liver. The gene discussed is GPT; the disease is fatty liver disease.